CLL Updates from ASH 2023
Impact of Ibrutinib Dose Reduction on Duration of Therapy in Patients With CLL/SLL
By
Insights from 2023 ASH Annual Meeting
FEATURING
Mazyar Shadman
By
Insights from 2023 ASH Annual Meeting
FEATURING
Mazyar Shadman
Comments 0
Login to view comments.
Click here to Login
